Zobrazeno 1 - 10
of 32
pro vyhledávání: '"J. Russell Lipford"'
Autor:
Chuanchuan Li, Britta Weigelt, Mark Li, Elisa de Stanchina, Yonina R. Murciano-Goroff, Kanika Arora, Lee P. Lim, Jorge S. Reis-Filho, Jenny Y. Xue, Dongsung Kim, Rohan S. Roy, Yulei Zhao, Michael F. Berger, Amber Bahr, Ann E. Sisk, Brian Loomis, Deanna Mohn, Pragathi Achanta, Trang Thi Mai, Agnes Ang, Bob T. Li, Arnaud Da Cruz Paula, Gregory J. Riely, Kathryn C. Arbour, Jessica Lucas, Piro Lito, J. Russell Lipford, Anne Y. Saiki
Publikováno v:
Nature
Inactive state-selective KRAS(G12C) inhibitors1–8 demonstrate a 30–40% response rate and result in approximately 6-month median progression-free survival in patients with lung cancer9. The genetic basis for resistance to these first-in-class muta
Autor:
Chendi Li, Mohammed Usman Syed, Yi Shen, Cameron Fraser, Jian Ouyang, Johannes Kreuzer, Sarah E. Clark, Audris Oh, Makeba Walcott, Robert Morris, Christopher Nabel, Sean Caenepeel, Anne Y. Saiki, Karen Rex, J. Russell Lipford, Rebecca S. Heist, Jessica J. Lin, Wilhelm Haas, Kristopher Sarosiek, Paul E. Hughes, Aaron N. Hata
The recently approved KRASG12C inhibitor sotorasib induces durable responses of KRASG12C-mutant non-small cell lung cancers (NSCLCs), however, some patients do not derive benefit. Identification of specific vulnerabilities conferred by co-occurring m
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::35abba6c3c548a2ab22035c3c220edca
https://doi.org/10.1101/2022.09.29.510137
https://doi.org/10.1101/2022.09.29.510137
Autor:
Deanna Mohn, Anne Y. Saiki, Pragathi Achanta, Andres Plata Stapper, J. Russell Lipford, Rati Verma
Publikováno v:
Cancer Research. 83:3871-3871
Sotorasib is an approved KRASG12C-selective inhibitor for the treatment of KRAS p.G12C-mutant advanced and previously treated non-small cell lung cancers (NSCLC). Acquired resistance due to genomic alterations following sotorasib treatment has been o
Autor:
Brian A. Lanman, Jennifer R. Allen, John G. Allen, Albert K. Amegadzie, Kate S. Ashton, Shon K. Booker, Jian Jeffrey Chen, Ning Chen, Michael J. Frohn, Guy Goodman, David J. Kopecky, Longbin Liu, Patricia Lopez, Jonathan D. Low, Vu Ma, Ana E. Minatti, Thomas T. Nguyen, Nobuko Nishimura, Alexander J. Pickrell, Anthony B. Reed, Youngsook Shin, Aaron C. Siegmund, Nuria A. Tamayo, Christopher M. Tegley, Mary C. Walton, Hui-Ling Wang, Ryan P. Wurz, May Xue, Kevin C. Yang, Pragathi Achanta, Michael D. Bartberger, Jude Canon, L. Steven Hollis, John D. McCarter, Christopher Mohr, Karen Rex, Anne Y. Saiki, Tisha San Miguel, Laurie P. Volak, Kevin H. Wang, Douglas A. Whittington, Stephan G. Zech, J. Russell Lipford, Victor J. Cee
Publikováno v:
Journal of Medicinal Chemistry. 63:52-65
Autor:
Timothy J. Price, Victor J. Cee, Tisha San Miguel, Gerald Steven Falchook, Jonathan Werner, Christopher Mohr, Tao Osgood, James Kuo, Kevin Gaida, Xiaochun Zhu, Karen Rex, John D. McCarter, Brian A. Lanman, H. Henary, Roberto Ortiz, Ramaswamy Govindan, Tara Arvedson, Laurie P. Volak, Wenjun Ouyang, J. Russell Lipford, Tyler Holt, Charles G. Knutson, Neelima Koppada, David S. Hong, Aaron S. Rapaport, Anne Y. Saiki, Bert H. O'Neil, Jude Canon, Ji Rong Sun, Marwan Fakih, Brett E. Houk, Dhanashri Bagal, Keegan Cooke, Jayesh Desai
Publikováno v:
Nature. 575:217-223
KRAS is the most frequently mutated oncogene in cancer and encodes a key signalling protein in tumours1,2. The KRAS(G12C) mutant has a cysteine residue that has been exploited to design covalent inhibitors that have promising preclinical activity3–
Autor:
Hui-Ling Wang, Kristin L. Andrews, Shon K. Booker, Jude Canon, Victor J. Cee, Frank Chavez, Yuping Chen, Heather Eastwood, Nadia Guerrero, Brad Herberich, Dean Hickman, Brian A. Lanman, Jimmy Laszlo, Matthew R. Lee, J. Russell Lipford, Bethany Mattson, Christopher Mohr, Yen Nguyen, Mark H. Norman, Liping H. Pettus, David Powers, Anthony B. Reed, Karen Rex, Christine Sastri, Nuria Tamayo, Paul Wang, Jeffrey T. Winston, Bin Wu, Qiong Wu, Tian Wu, Ryan P. Wurz, Yang Xu, Yihong Zhou, Andrew S. Tasker
Publikováno v:
Journal of Medicinal Chemistry. 62:1523-1540
Pim kinases are a family of constitutively active serine/threonine kinases that are partially redundant and regulate multiple pathways important for cell growth and survival. In human disease, high expression of the three Pim isoforms has been implic
Autor:
Chendi Li, Mohammed Usman Syed, Yi Shen, Audris Oh, Cameron Fraser, Johannes Kreuzer, Christopher Nabel, Kaitlyn Webster, Robert Morris, Sean Caenepeel, Anne Y. Saiki, Karen Rex, J. Russell Lipford, Wilhelm Hass, Kristopher Sarosiek, Paul E. Hughes, Aaron Hata
Publikováno v:
Cancer Research. 82:2150-2150
The recent approval of the KRAS G12C inhibitor sotorasib (AMG 510) for non-small cell lung cancer (NSCLC) marked a milestone in the development of targeted therapies for KRAS mutant cancers. While sotorasib and other KRAS G12C inhibitors have demonst
Autor:
Jonathan A, Werner, Rhian, Davies, Jan, Wahlstrom, Upendra P, Dahal, Min, Jiang, Jonathan, Stauber, Benjamin, David, William, Siska, Barbara, Thomas, Katsu, Ishida, W Griffith, Humphreys, J Russell, Lipford, Thomas M, Monticello
Publikováno v:
Toxicology and applied pharmacology. 423
Sotorasib is a first-in class KRAS
Autor:
H. Henary, John C. Krauss, Timothy J. Price, Geoffrey I. Shapiro, Marwan Fakih, Timothy F. Burns, Jayesh Desai, Crystal S. Denlinger, John H. Strickler, Keunchil Park, Brett E. Houk, Funda Meric-Bernstam, Ramaswamy Govindan, J. Russell Lipford, Fabrice Barlesi, Andrew L. Coveler, James Kuo, Gregory Friberg, Adrian G. Sacher, Tae Won Kim, Pamela N. Munster, Gataree Ngarmchamnanrith, J. Kim, Jude Canon, David S. Hong, Gerald S. Falchook, Piro Lito, Yung-Jue Bang, Bob T. Li, Yasutoshi Kuboki, J. Ngang, G. Durm, Grace K. Dy, Suresh S. Ramalingam
Publikováno v:
N Engl J Med
BACKGROUND: No therapies for targeting KRAS mutations in cancer have been approved. The KRAS p.G12C mutation occurs in 13% of non–small-cell lung cancers (NSCLCs) and in 1 to 3% of colorectal cancers and other cancers. Sotorasib is a small molecule
Autor:
Victor J. Cee, Alla Verlinsky, Anne Y. Saiki, Brian A. Lanman, Marwan Fakih, J. Russell Lipford, Tyler Holt, Patricia McElroy, Karen Rex, Ji-Rong Sun, Jude Canon, Tao Osgood, Upendra P. Dahal, Bernd Bruenner
Publikováno v:
Cancer Research. 81:1057-1057
KRAS is the most frequently mutated oncogene in cancer and encodes a key signaling protein in tumors. The p.G12C mutation of KRAS is present in approximately 13% of lung adenocarcinoma, 3% of colorectal cancer, and 2% of other solid tumors. Sotorasib